We describe our experience using this combined target therapy for two patients with BRAF<sup>V600E</sup> mutant glioblastoma (GBM) as primary treatment due to extenuating clinical circumstances that prohibited the prescription of standard treatment.<h4>Case presentation</h4>The two patients were both 22 years old on presentation. Here, BRAF is linked to glioblastoma.